Fullerenol-cytotoxic conjugates for cancer chemotherapy

ACS Nano

Volumn 3, Issue 9, 2009, Pages 2505-2514

  Chaudhuri, Padmaparna ^a,b   Paraskar, Abhimanyu ^a,b   Soni, Shivani ^a,b   Mashelkar, Raghunath A ^a,c   Sengupta, Shiladitya ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MIT DIVISION OF HEALTH SCIENCES AND TECHNOLOGY   (United States)

^c NATIONAL CHEMICAL LABORATORY   (India)

Author keywords

Chemotherapy; Delivery; Doxorubicin; Drug; Fullerenol; Nanoparticle

Indexed keywords

ACTIVE DRUGS; ANTI-TUMOR EFFICACY; APOPTOSIS; CANCER CELLS; CANCER CHEMOTHERAPY; CANCER DRUG; CELL CYCLE; CHEMOTHERAPEUTIC AGENTS; CIS-PLATIN; CYTOTOXIC; DELIVERY; DOXORUBICIN; DOXORUBICIN CONJUGATES; DRUG; DRUG LOADING; FULLERENE CAGES; FULLERENOL; FULLERENOLS; HYDROXYL GROUPS; IN-VITRO; IN-VIVO; LOADING EFFICIENCY; NOVEL APPLICATIONS; PHOSPHATE BUFFER SALINES; SYNTHETIC PROCEDURES; TUMOR CELLS; TUMOR MODELS;

CELL DEATH; CELL MEMBRANES; CHEMOTHERAPY; DRUG DELIVERY; NANOPARTICLES; PLATINUM COMPOUNDS; TUMORS;

FULLERENES;

ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; DRUG CARRIER; FULLERENE DERIVATIVE; FULLERENOL; HYDROXIDE; HYDROXIDE ION; NANOPARTICLE; WATER;

ANIMAL; APOPTOSIS; ARTICLE; CELL CYCLE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECT; FLOW CYTOMETRY; HUMAN; MELANOMA; METABOLISM; MOUSE; PATHOLOGY; PH; SOLUBILITY; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL TRANSPORT; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; DOXORUBICIN; DRUG CARRIERS; FLOW CYTOMETRY; FULLERENES; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROXIDES; MELANOMA; MICE; NANOPARTICLES; SOLUBILITY; WATER;

EID: 70349545949     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn900318y     Document Type: Article

References (32)

1. US Department of Health and Human Services. National Institute of Health & National Cancer Institute. A Strategic Initiative to Transform Clinical Oncology and Basic Research Through the Directed Application of Nanotechnology. http://nano.cancer.gov/about-alliance/cancer-nanotechnology-plan.asp, July 2004.
2. Ferrari, M. Cancer Nanotechnology: Opportunities and Challenges. Nat. Rev. Cancer 2005, 5, 161-171.
3. Gabizon, A. A.; Shmeeda, H.; Zalipsky, S. Pros and Cons of the Liposome Platform in Cancer Drug Targeting. J Liposome Res. 2006, 16, 175-183.
4. Duncan, R. The Dawning Era of Polymer Therapeutics. Nat. Rev. Drug Discovery 2003, 2, 347-360.
5. Gillies, E. R.; Frechet, J. M. J. Dendrimers and Dendritic Polymers in Drug Delivery. Drug Discovery Today 2005, 10, 35-43.
6. Geng, Y.; Dalhaimer, P.; Cai, S.; Tsai, R.; Tewari, M.; Minko, T.; Discher, D. E. Shape Effects of Filaments versus Spherical Particles in Flow and Drug Delivery. Nat. Nanotechnol. 2007, 2, 249-255. (Pubitemid 46739812)
7. Nakamura, E.; Isobe, H. Functionalized Fullerenes in Water. The First 10 Years of Their Chemistry, Biology, and Nanoscience. Acc. Chem. Res. 2003, 36, 807-815.
8. Liu, Z.; Chen, K.; Davis, C.; Sherlock, S.; Cao, Q.; Chen, X.; Dai, H. Drug Delivery with Carbon Nanotube for in Vivo Cancer Treatment. Cancer Res. 2008, 68, 6652-6660.
9. Zerda, A. D. L.; Zavaleta, C.; Karen, S.; Vaithilingam, S.; Bodapati, S.; Liu, Z.; Levi, J.; Smith, B. R.; Ma, T. -J.; Oralkan, O.; Chang, Z.; Chen, X.; Dai, H.; Khuri-Yakub, B. T.; Gambhir, S. S. Carbon Nanotubes as Photoacoustic Molecular Imaging Agents in Living Mice. Nat. Nanotechnol. 2008, 3, 557-562.
10. Foley, S.; Crowley, C; Smaihi, M.; Bonfils, C; Erlanger, B. F.; Seta, P.; Larroque, C. Cellular Localization of a Water-Soluble Fullerene Derivative. Biochem. Biophvs. Res. Commun. 2002, 294, 116-119.
11. Bakry, R.; Valiant, R. M.; Najam-ul-Haq, M.; Rainer, M.; Szabo, Z.; Huck, C. W.; Bonn, G. K. Medical Applications of Fullerenes. Int. J. Nanomed. 2007, 2, 639-649.
12. Isobe, H.; Nakanishi, W.; Tomita, N.; Jinno, S.; Okayama, H.; Nakamura, E. Nonviral Gene Delivery by Tetraamino Fullerene. Mol. Pharm. 2006, 3, 124-134.
13. Marchesan, S.; Da Ros, T.; Spalluto, G.; Balzarini, J.; Prato, M. Anti-HIV Properties of Cationic Fullerene Derivatives. Bioora. Med. Chem. 2005, 15, 3615-3618.
14. Mroz, P.; Tegos, G. P.; Gali, H.; Wharton, T.; Sarna, T.; Hamblin, M. R. Photodynamic Therapy with Fullerenes. Photochem. Photobiol. Sci. 2007, 6, 1139-1149
15. Ali, S. S.; Hardt, J. I.; Quick, K. L; Kim-Han, J. S.; Erlanger, B. F.; Huang, T. T.; Epstein, C. J.; Dugan, L. L. A Biologically Effective Fullerene (C60) Derivative with Superoxide Dismutase Mimetic Properties. Free Radical Biol. Med. 2004, 37, 1191-1202.
16. Wharton, T.; Wilson, L.J. Highly-lodinated Fullerene as a Contrast Agent for X-ray Imaging. Bioora. Med. Chem. 2002, 10, 3545-3554.
17. Cagle, D. W.; Kennel, S. J.; Mirzadeh, S.; Alford, J. M.; Wilson, L. J. In Vivo Studies of Fullerene-Based Materials Using Endohedral Metallofullerene Radiotracers. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 5182-5187.
18. Mikawa, M.; Kato, H.; Okumura, M.; Narazaki, M.; Kanawaza, Y.; Miwa, N.; Shinohara, H. Paramagnetic Water-Soluble Metallofullerenes Having the Highest Relaxivity for MRI Contra st Agents. Bioconiuaate Chem. 2001, 12, 510-514.
19. Ashcroft, J. M.; Tsyboulski, D. A.; Hartman, K. B.; Zakharian, T. Y.; Marks, J. W.; Weiman, R. B.; Rosenblum, M. G.; Wilson, L. J. Fullerene (C60) Immunoconjugtes: Interaction of Water-Soluble C60 Derivatives with the Murine Anti-gp240 Melanoma Antibody. Chem. Commun. 2006, 3004-3006.
20. Zakharian, T. Y.; Seryshev, A.; Sitharaman, B.; Gilbert, B. E.; Knight, V.; Wilson, L. J. A Fullerene-Paclitaxel Chemotherapeutic: Synthesis, Characterization, and Study of Biological Activity in Tissue Culture. J. Am. Chem. Soc. 2005, 127, 12508-12509.
21. Partha, R.; Mitchell, L. R.; Lyon, J. L.; Joshi, P. P.; Conyers, J. L. Buckysomes: Fullerene-Based Nanocarriers for Hydrophobic Molecule Delivery. ACS Nano 2008, 2, 1950-1958.
22. Kokubo, K.; Matsubayashi, K.; Tategaki, H.; Takada, H.; Oshima, T. Facile Synthesis of Highly Water-Soluble Fullerenes More Than Half-Covered by Hydroxyl Groups. ACS Nano 2007, 2, 327-333.
23. Peer, D.; Karp, J. M.; Hong, S.; Farokhzad, O. C; Margalit, R.; Langer, R. Nanocarriers as an Emerging Platform for Cancer Therapy. Nat. Nanotechnol. 2007, 2, 751-760.
24. Basu, S.; Harfouche, R.; Soni, S.; Chimote, G.; Mashelkar, R. A.; Sengupta, S. Nanoparticle-Mediated Targeting of MAPK Signaling Predisposes Tumor to Chemotherapy. Proc. Natl. Acad. Sci. U.S.A. 2009, 706, 7957-7961.
25. Ruoslahti, E.; Duza, T.; Zhang, L. Vascular Homing Peptides with Cell-Penetrating Properties. Curr. Pharm. Pes. 2005, 11, 3655-3660.
26. Xu, G.; Zhang, W.; Ma, M. K.; McLeod, H. Z. Human Carboxylesterase2 Is Commonly Expressed in Tumor Tissue and Is Correlated with Activation of Irinotecan. Clin. Cancer. Res. 2002, 8, 2605-2611.
27. Devi, L.; De Grot, F. M. H.; Blacher, S.; Hajitou, A.; Beusker, P. H.; Scheeren, H. W.; Foidart, J. -M.; Noel, A. Plasmin-Activated Doxorubicin Prodrugs Containing a Spacer Reduce Tumor Growth and Angiogenesis Without Systemic Toxicity. FASEB J. 2004, 18, 564-567.
28. OKunewick, J. P.; Buffo, M. J.; Kociban, D. L. Comparative Toxicity of Mitoxantrone and Doxorubicin on Hematopoietic Stem Cells. Exp. Hematol. 1985, 13, 23-30.
29. Ruchatz, H.; Puttini, M.; Cleris, L; Pilotti, S.; Gambacorti-Passerini, C; Formelli, F. Effect of Imatinib on Haematopoietic Recovery Following Idarubicin Exposure. Leukemia 2003, 17, 298-304.
30. Hamed, S.; Barshack, I.; Luboshits, G.; Wexler, D.; Deutsch, V.; Keren, G.; George, J. Erythropoietin Improves Myocardial Performance in Doxorubicin-lnduced Cardiomyopathy. Eur. Heart J. 2006, 27, 1876-1883.
31. Schipper, M. L; Nakayama-Ratchford, N.; Davis, C. R.; Kam, N. W.; Chu, P.; Liu, Z.; Sun, X.; Dai, H.; Gambhir, S. S. A Pilot Toxicology Study of Single-Walled Carbon Nanotubes in a Small Sample of Mice. Nat Nanotechnol. 2008, 3, 216-221.
32. Scheechter, B.; Pauzner, R.; Arnon, R.; Wilchek, M. Cis-platinum(ll) Complexes of Carboxymethyl-Dextran as Potential Antitumor Agents I. Preparation and Characterization. Cancer Biochem. Biophvs. 1986, 8, 277-287.